Overview: Galectin-3 TestIntroduction: The Galectin-3 Test measures galectin-3 to assess heart failure or cancer risk, causing shortness of breath or fatigue. Following 2023 ACC and ASCO guidelines, it uses an immunoassay for high sensitivity, aiding in cancer and cardiac screening. This test is critical for guiding diagnosis, risk assessment, and improving outcomes in immunology for patients with suspected heart failure or cancer.
Other Names: Galectin-3 Assay, Cardiac Fibrosis Marker Test.
FDA Status: FDA-cleared diagnostic test, meeting immunology standards for diagnostic accuracy.
Historical Milestone: Galectin-3 testing began in the 2000s with heart failure research. Immunoassays emerged in the 2010s, improving accuracy for cardiac and cancer risk assessment.
Purpose: Assesses heart failure or cancer risk, guides treatment, and monitors galectin-3 levels in patients with shortness of breath or fatigue.
Test Parameters: 1. Galectin-3
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like shortness of breath or fatigue, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document shortness of breath, fatigue, or history of heart failure/cancer. Include current medications, especially cardiac or chemotherapeutic drugs.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for treatment.
Procedural Considerations: Uses an immunoassay to measure galectin-3 levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis or improper storage can affect results. Inflammatory conditions may elevate levels.
Clinical Significance: Elevated galectin-3 levels suggest heart failure or cancer risk, prompting treatment or monitoring. Normal levels may require further testing.
Specialist Consultation: Consult a cardiologist or oncologist for result interpretation.
Additional Supporting Tests: BNP, troponin, or imaging (e.g., PET scan) to confirm heart failure or cancer.
Test Limitations: Non-specific elevations may occur in inflammation. Results require clinical correlation.
References: ACC Heart Failure Guidelines, 2023; Journal of Clinical Oncology, McCullough PA, 2022.
